InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,474.55
(
0.18%
)
US TECH 100
19,177.20
(
-0.16%
)
Dow Jones
39,466.74
(
0.81%
)
Brent Oil
84.89
(
1.04%
)
Bitcoin
61,229.07
(
-3.05%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

surf1944

Send PM Follow Ignore
Followers 467
Posts 26931
Boards Moderated 2
Alias Born 09/11/2006

surf1944

Re: None

Tuesday, 05/04/2010 9:36:29 AM

Tuesday, May 04, 2010 9:36:29 AM

Post# of 177
7:41AM Pharmasset stated that the development of RG7128 is on track, and that no safety or other concerns have delayed the program. (VRUS) 32.74 : VRUS, in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus (HCV) in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.


surf's up......crikey



Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up